Thematics Asset Management Boosts Stake in Exact Sciences Co. (NASDAQ:EXAS)

Thematics Asset Management boosted its position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 26.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 87,572 shares of the medical research company's stock after acquiring an additional 18,451 shares during the period. Thematics Asset Management's holdings in Exact Sciences were worth $4,921,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of EXAS. Ostrum Asset Management increased its holdings in Exact Sciences by 28.4% in the fourth quarter. Ostrum Asset Management now owns 2,382 shares of the medical research company's stock valued at $134,000 after buying an additional 527 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S boosted its position in shares of Exact Sciences by 662.8% during the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 20,290 shares of the medical research company's stock worth $1,140,000 after acquiring an additional 17,630 shares in the last quarter. Capital World Investors increased its holdings in shares of Exact Sciences by 10.7% in the 4th quarter. Capital World Investors now owns 17,537,617 shares of the medical research company's stock valued at $985,439,000 after acquiring an additional 1,696,321 shares during the last quarter. Curi RMB Capital LLC raised its position in shares of Exact Sciences by 1.7% during the 4th quarter. Curi RMB Capital LLC now owns 24,896 shares of the medical research company's stock worth $1,399,000 after acquiring an additional 428 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Exact Sciences by 20.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 969,185 shares of the medical research company's stock worth $54,461,000 after purchasing an additional 165,809 shares during the last quarter. 88.82% of the stock is owned by hedge funds and other institutional investors.

Exact Sciences Price Performance

Shares of NASDAQ EXAS traded down $0.07 on Friday, hitting $45.54. The company's stock had a trading volume of 649,994 shares, compared to its average volume of 2,604,966. The stock has a 50 day moving average of $45.42 and a 200-day moving average of $54.38. The company has a market capitalization of $8.46 billion, a price-to-earnings ratio of -8.18 and a beta of 1.14. Exact Sciences Co. has a 12-month low of $39.97 and a 12-month high of $72.83. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The firm had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. As a group, research analysts predict that Exact Sciences Co. will post -0.58 EPS for the current year.

Wall Street Analyst Weigh In

EXAS has been the topic of a number of research analyst reports. Benchmark reissued a "buy" rating and set a $65.00 price objective on shares of Exact Sciences in a report on Monday, January 13th. Barclays dropped their price objective on Exact Sciences from $65.00 to $55.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Bank of America reduced their target price on Exact Sciences from $72.00 to $65.00 and set a "buy" rating for the company in a report on Thursday, February 20th. Scotiabank lifted their price target on Exact Sciences from $70.00 to $73.00 and gave the stock a "sector outperform" rating in a research report on Monday, February 24th. Finally, Mizuho began coverage on Exact Sciences in a report on Thursday, April 10th. They issued an "outperform" rating and a $60.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $69.25.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.